Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.64 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779180 | 0.89 | MAP3K7 (0.54) | MAP3K7TAB1BCL2MCL1LCK | |
| SCHEMBL4779176 | 0.89 | MAP3K7 (0.54) | MAP3K7TAB1BCL2MCL1LCK | |
| SCHEMBL4795882 | 0.89 | MAP3K7 (0.56) | MAP3K7TAB1LCKMAPT | |
| SCHEMBL4779169 | 0.88 | MAP3K7 (0.60) | MAP3K7TAB1SNCATERTMAPT | |
| SCHEMBL4979980 | 0.87 | MAP3K7 (0.50) | MAP3K7TAB1BCL2MCL1 | |
| SCHEMBL14273443 | 0.87 | MAP3K7 (0.50) | MAP3K7TAB1BCL2MCL1 | |
| SCHEMBL4726277 | 0.86 | MAP3K7 (0.59) | MAP3K7TAB1SNCATERTMAPT | |
| SCHEMBL4982661 | 0.84 | MAP3K7 (0.54) | MAP3K7TAB1LCK | |
| SCHEMBL4982657 | 0.84 | MAP3K7 (0.54) | MAP3K7TAB1LCK | |
| SCHEMBL4981501 | 0.82 | MMP9 (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | MAP3K7 1090/4885TAB1 981/4885BCL2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.